paclitaxel-carboplatin
Showing 1 - 25 of 4,872
Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)
Recruiting
- Locally Advanced Breast Cancer
- Chemotherapy Effect
- inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
-
Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Feb 28, 2023
Endometrial Carcinoma Trial in Sohag (Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin)
Not yet recruiting
- Endometrial Carcinoma
-
Sohag, EgyptSohag university Hospital
Oct 25, 2023
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom
Active, not recruiting
- Triple Negative Metastatic Breast Cancer
- +3 more
- KU-0059436 (AZD2281)(PARP inhibitor)
- +3 more
-
Brussels, Belgium
- +3 more
Dec 19, 2022
NSCLC Trial in Russian Federation (Bevacizumab, Paclitaxel, Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Bevacizumab
- +2 more
-
Arkhangel'sk, Russian Federation
- +10 more
Dec 8, 2022
Ovarian Tumor Epithelial, Ovarian Cancer, Fallopian Tube Tumors Trial in India (Oregovomab, Paclitaxel, Carboplatin)
Not yet recruiting
- Ovarian Neoplasm Epithelial
- +4 more
- Oregovomab
- +3 more
-
Visakhapatnam, Andhra Pradesh, India
- +7 more
Dec 7, 2022
Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)
Not yet recruiting
- Recurrent Ovarian Cancer
- +3 more
- RP-6306
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Oct 25, 2023
NSCLC, Squamous Cell Carcinoma Trial in Wuhan (Nab-paclitaxel, Carboplatin, Thoracic radiation therapy)
Terminated
- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma
- Nab-paclitaxel
- +2 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Apr 26, 2022
NSCLC(NSCLC) Trial in Nanjing (BP102, paclitaxel, carboplatin, Avastin®, paclitaxel, carboplatin)
Completed
- Non-small Cell Lung Cancer(NSCLC)
- BP102, paclitaxel, carboplatin
- Avastin®, paclitaxel, carboplatin
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Dec 23, 2021
Head and Neck Squamous Cell Carcinoma Trial in United States (TAK-676, Carboplatin, 5-FU)
Completed
- Head and Neck Squamous Cell Carcinoma
- TAK-676
- +8 more
-
Shreveport, Louisiana
- +3 more
Oct 3, 2023
Advanced Epithelial Ovarian Cancer Trial in Cairo (Carboplatin/paclitaxel)
Completed
- Advanced Epithelial Ovarian Cancer
-
Cairo, EgyptPharmacology and toxicology department, Faculty of Pharmacy, Cai
Jul 19, 2023
Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)
Recruiting
- Breast Cancer
- Neoadjuvant
- pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
-
Wuhan, Hubei, China
- +1 more
Aug 18, 2023
HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,
Recruiting
- HNSCC
- +2 more
- Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
- Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
-
Guangzhou, Guangdong, ChinaSun yat-sen memorial hospital
Aug 6, 2023
Head and Neck Squamous Cell Carcinoma Trial in Seoul (paclitaxel/carboplatin)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Mar 24, 2022
Head and Neck Squamous Cell Carcinoma, Oral Cancer Trial in Guangzhou (Tirelizumab ,+Carboplatin+albumin-bound paclitaxel)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Oral Cancer
- Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
-
Guangzhou, Guangdong, ChinaSun yat-sun memorial hospital
Jul 10, 2023
Melanoma Trial in Beijing (tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin)
Not yet recruiting
- Melanoma
- tunlametinib
- paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Aug 15, 2023
Adult Solid Tumor Trial in Chicago (Carboplatin, Laboratory Biomarker Analysis, Paclitaxel)
Active, not recruiting
- Adult Solid Neoplasm
- Carboplatin
- +4 more
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Jan 25, 2023
Lung Cancer Trial in Carlsbad, Cleveland (ISIS 3521, carboplatin, paclitaxel)
Completed
- Lung Cancer
- ISIS 3521
- +2 more
-
Carlsbad, California
- +1 more
Dec 1, 2022
NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer Metastatic
- Atezolizumab
- +5 more
- (no location specified)
Jan 18, 2023
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma Trial in Guangzhou, Guanzhou (sintilimab, paclitaxel,
Recruiting
- Oral Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- sintilimab, paclitaxel, carboplatin
- Surgical resection
-
Guangzhou, Guangdong, China
- +1 more
Feb 23, 2022
Oropharynx Squamous Cell Carcinoma Trial in Ann Arbor (Nivolumab, Carboplatin, Paclitaxel)
Active, not recruiting
- Oropharynx Squamous Cell Carcinoma
- Nivolumab
- +3 more
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Dec 20, 2022
Head Neck Cancer Trial in Singapore (carboplatin,, cisplatin, gemcitabine HCl)
Active, not recruiting
- Head and Neck Cancer
- carboplatin,
- +4 more
-
Singapore, SingaporeNational Cancer Centre - Singapore
Sep 27, 2022
Breast Cancer Trial in United States (carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat)
Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV Trial in Seoul (Oregovomab, Bevacizumab,
Recruiting
- Ovarian Cancer by FIGO Stage
- +2 more
- Oregovomab
- +3 more
-
Daegu, Korea, Republic of
- +5 more
Oct 20, 2022
Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)
Completed
- Breast Cancer
- Panitumumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 20, 2022